

RECEIVED
CENTRAL FAX CENTER

MAY 24 2005

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the applications:

Listing of Claims:

Claims 1-3 (canceled)

12. (previously presented) A vector comprising the nucleic acid molecule of claim 100.

3. (previously presented) An isolated host cell comprising the nucleic acid molecule of claim 100.

4. (previously presented) An isolated host cell comprising the nucleic acid molecule of claim 100 operatively linked to a regulatory sequence other than the promoter for a native IL-17 receptor like polypeptide.

15. (previously presented) An isolated host cell modified by transformation or transfection with a regulatory nucleic acid, wherein said regulatory nucleic acid promotes transcription or translation of a nucleic acid comprising the sequence of SEQ ID NO: 1, 4, or 6.

16. (original) The host cell of claim 7 wherein the regulatory nucleic acid sequence is a promoter.

17. (original) The host cell of claim 7 wherein the regulatory nucleic acid is a transcription factor.

5. (previously presented) The host cell of claim 3 that is a eukaryotic cell.

6. (previously presented) The host cell of claim 5 that is a prokaryotic cell.

~~12~~ (previously presented) A process of producing an IL-17 receptor like polypeptide comprising culturing the host cell of claim ~~8~~⁷ under suitable conditions to express the polypeptide, and optionally isolating the polypeptide from the culture.

Claim 13 (canceled)

~~14~~ (previously presented) The process of any one of claims ~~12~~⁷, ~~17~~⁹ and ~~18~~ wherein the nucleic acid molecule comprises promoter DNA other than the promoter DNA for the native IL-17 receptor like polypeptide operatively linked to the DNA encoding the IL-17 receptor like polypeptide.

Claims 15-58 (canceled)

~~59~~¹⁰ (previously amended) A composition comprising a nucleic acid molecule of claim 100 and a pharmaceutically acceptable formulation agent.

~~60~~¹¹ (previously presented) A composition of claim 59 wherein said nucleic acid molecule is contained in a viral vector.

~~61~~¹² (previously presented) A viral vector comprising a nucleic acid molecule of claim 100.

Claims 62-73 (canceled)

~~74~~¹⁹ (currently amended) A diagnostic reagent comprising a detectably labeled polynucleotide, ~~encoding the amino acid sequence set out in at least one of SEQ ID NO: 2, SEQ ID NO: 5 or SEQ ID NO: 7 wherein the polynucleotide encodes a polypeptide comprising an amino acid sequence selected from the group consisting of:~~

(a) amino acids 1 through 560 of SEQ ID NO: 5,

(b) amino acids 1 through 350 of SEQ ID NO: 5, and

(c) amino acids 14 through 350 of SEQ ID NO: 5.

~~75~~²⁰ (original) The diagnostic reagent of claim 74, wherein said labeled polynucleotide is a first-strand cDNA.

Claims 76-90 (canceled)

17 91. (previously presented) ~~the~~ An isolated nucleic acid molecule of claim 100 wherein the nucleic acid molecule encodes a polypeptide that induces inflammation.

14 92. (previously presented) ~~the~~ An isolated nucleic acid molecule of claim 100 wherein the nucleic acid molecule encodes a polypeptide that induces myelopoiesis.

Claims 93-96 (canceled)

9 97. (previously presented) A process of producing an IL-17 receptor like polypeptide comprising culturing the host cell of claim 6 under suitable conditions to express the polypeptide, and optionally isolating the polypeptide from the culture.

16 98. (previously presented) A process of producing an IL-17 receptor like polypeptide comprising culturing the host cell of claim 7 under suitable conditions to express the polypeptide, and optionally isolating the polypeptide from the culture.

99. (canceled)

1 100. (previously presented) An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

(a) ~~the~~ a nucleotide sequence comprising nucleotides 50 through 1729 of SEQ

ID NO: 4;

(b) ~~the~~ a nucleotide sequence comprising nucleotides 50 through 1099 of SEQ

ID NO: 4;

(c) ~~the~~ a nucleotide sequence comprising nucleotides 89 through 1099 of SEQ

ID NO: 4;

(d) ~~the~~ a nucleotide sequence encoding a polypeptide comprising amino acids

1 through 560 of SEQ ID NO: 5;

(e) ~~the~~ a nucleotide sequence encoding a polypeptide comprising amino acids

1 through 350 of SEQ ID NO: 5;

(f) ~~the~~ a nucleotide sequence encoding a polypeptide comprising amino acids 14 through 350 of SEQ ID NO: 5;

(g) ~~the~~ a nucleotide sequence encoding a polypeptide having an amino acid sequence that is at least 90 percent identical to amino acids 14 through 350 of SEQ ID NO: 5, wherein the polypeptide binds IL-17; and


(h) ~~the~~ a nucleotide sequence fully complementary to any of (a)-(g).

101. (canceled).

~~21~~ 102. (previously presented) An isolated nucleic acid molecule comprising a nucleotide sequence of the cDNA clone contained in ATCC deposit number PTA-3176. ~~the~~

~~22~~ 103. (previously presented) An isolated nucleic acid molecule comprising a nucleotide sequence, wherein the nucleotide sequence encodes a polypeptide comprising the extracellular domain of an amino acid sequence encoded by the cDNA clone contained in ATCC deposit number PTA-3177.

~~23~~ 104. (previously presented) An isolated nucleic acid molecule comprising a nucleotide sequence of the cDNA clone contained in ATCC deposit number PTA-3178. ~~the~~

~~24~~ 105. (new) An isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having an amino acid sequence that is at least 90 percent identical to amino acids 14 through 350 of SEQ ID NO: 5, wherein the polypeptide binds IL-17. 

~~25~~ 106. (new) An isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide comprising amino acids 14 through 350 of SEQ ID NO: 5.

~~26~~ 107. (new) An isolated nucleic acid molecule comprising a nucleotide sequence comprising nucleotides 89 through 1099 of SEQ ID NO: 4.